Monday, February 10, 2025 2/10/2025

Evaluating candidate mediators of prostate cancer metastasis and neuro endocrine prostate cancer (NEPC) trans differentiation

Award Number: R50CA221786
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Prostate cancer relapsing from antiandrogen therapies can exhibit variant histology with altered lineage marker expression, suggesting lineage plasticity facilitates therapeutic resistance. Mechanisms underlying prostate cancer lineage plasticity are unknown. Our recent work published in Science uses mouse models of prostate cancer to demonstrate Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. The research program funded by R01 CA207757 proposes to identify molecular mechanisms underlying Rb1 and Trp53 function in this context and assess a novel therapeutic approach using epigenetic modulating drugs to improve responses to therapy. This R50 application proposes salary support for Meenalakshmi Chinnam, Ph.D. to support the R01 CA207757 research program. Dr. Chinnam works as a Research Associate in the laboratory of Dr. David Goodrich, unit director on this application. Dr. Chinnam has made significant contributions to Dr. Goodrich's research programs since 2004, and her work has been published in well-regarded journals. Dr. Chinnam is a skilled experimentalist with a broad background in pharmacology, molecular biology, molecular genetics, biochemistry and nutrition sciences. She has over 13 years of experience in cancer research. Relevant to this application, Dr. Chinnam has considerable experience using mouse models of prostate cancer and characterizing the histopathology of both mouse and human prostate cancer specimens. Dr. Chinnam will leverage this expertise to help generate and characterize novel mouse models proposed in R01 CA207757 to elucidate how Ezh2 or E2f1 activity influence lineage plasticity, cancer progression, and response to antiandrogens. She will also characterize human prostate cancer specimens for cross-species validation. Dr. Chinnam's contributions will be essential for successful completion of the R01 CA207757 research program.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	HEALTH RESEARCH, INC.	665 ELM ST	BUFFALO	NY	14203	ERIE	USA	Cancer Biology Research	000	5	12/17/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $130,212 )
2023	2023	HEALTH RESEARCH, INC.	ELM & CARLTON ST	BUFFALO	NY	14263	ERIE	USA	Cancer Biology Research	000	5	9/6/2023	NON-COMPETING CONTINUATION	$130,212
														Subtotal = $130,212

Issue Date FY: 2022 ( Subtotal = $130,212 )
2022	2022	HEALTH RESEARCH, INC.	ELM AND CARLTON ST	BUFFALO	NY	14263	ERIE	USA	Cancer Biology Research	000	4	8/25/2022	NON-COMPETING CONTINUATION	$130,212
														Subtotal = $130,212

Issue Date FY: 2021 ( Subtotal = $130,212 )
2021	2021	HEALTH RESEARCH, INC.	ELM AND CARLTON ST	BUFFALO	NY	14263	ERIE	USA	Cancer Biology Research	000	3	8/26/2021	NON-COMPETING CONTINUATION	$130,212
														Subtotal = $130,212

Issue Date FY: 2020 ( Subtotal = $130,212 )
2020	2020	HEALTH RESEARCH, INC.	ELM AND CARLTON ST	BUFFALO	NY	14263	ERIE	USA	Cancer Biology Research	001	2	8/18/2020	NON-COMPETING CONTINUATION	$130,212
2020	2018	HEALTH RESEARCH, INC.	ELM AND CARLTON ST	BUFFALO	NY	14263	ERIE	USA	Cancer Biology Research	000	1	4/9/2020	NEW	$0
														Subtotal = $130,212

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2018	HEALTH RESEARCH, INC.	ELM AND CARLTON ST	BUFFALO	NY	14263	ERIE	USA	Cancer Biology Research	000	1	8/28/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $130,212 )
2018	2018	HEALTH RESEARCH, INC.	ELM AND CARLTON ST	BUFFALO	NY	14263	ERIE	USA	Cancer Biology Research	000	1	9/14/2018	NEW	$130,212
														Subtotal = $130,212

Grand Total All Awards = $651,060

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Evaluating candidate mediators of prostate cancer metastasis and neuro endocrine prostate cancer (NEPC) trans differentiation

Award Number: R50CA221786

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer